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Abstract: The first C60(OH)24-DNA complex and its fluorescence enhancement is reported. 
The enhanced fluorescence intensity of fullerenol C60(OH)24 is in proportion to the concentration 
of DNA in the range of 1 × 10-9 to 8 × 10-5 molL-1 and the detection limit was 1.3 ng mL-1. 
Fullerenol C60(OH)24 binds significantly to the phosphate backbone of native dsDNA and 
to base-pairs within the major groove of sodium salt of dsDNA.
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Introduction
Nanoscale materials seems to offer great opportunities for biomedical applications 
such as therapeutic and diagnostic tools.1–9 Biomedical applications under develop-
ment include drug delivery systems targeted to the brain and cancer tissues, gene 
transfection, and intravascular nanosensor and nanorobotic devices for imaging and 
diagnosis.3,9
In this context, the biological activities of fullerene derivatives have attracted much 
attention in the past 25 years.10–17 As potent free-radical scavengers and antioxidants18–23 
the water-soluble polyhydroxylated [C60]fullerenes, fullerenols, exhibit an exciting 
range of biological activities as glutamate receptor antagonists,24 antiproliferative,25–27 
neuroprotective,28–31 and anticancer agents.32–37
Knowing the ways fullerenols interact with proteins and nucleotides is a prerequisite 
for understanding their biological effects at membrane penetration and the intracellular 
level, only two studies deal with their binding to proteins38,39 and their interaction with 
DNA has not been reported to date.
On the other hand, the solution-based assays and quantitative analysis of nucleic 
acids are critical in current biochemistry and biomedical science. Throughout the years, 
a number of fluorimetric methods for the determination of nucleic acids have been 
developed with ethidium bromide,40–42 lanthanide cations,43–45 ruthenium complexes,46–48 
and asymmetric cyanine dyes as fluorescence probes.49–51
Despite the prominence of fullerenes in bionanotechnology, the exploration of 
their fluorescent properties in solution remains still at a very early age. Several studies 
have been devoted to dsDNA/single-walled carbon nanotube hybrid systems,52,53 but 
only very few deal with their fluorescent proprieties54,55 when dispersed in aqueous 
solution.
Herein, we are happy to report the first complexation of dsDNA with C60(OH)24 in 
aqueous media in the absence of a buffer in physiological pH-range.International Journal of Nanomedicine 2009:4 194
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Materials and methods
C60 (99.5+%) was purchased from MER Corp (Tuscon, AZ, 
USA). KOH (99.99%, semiconductor grade) was purchased 
from Sigma-Aldrich (St. Louis, MO, USA). DNA (low 
molecular weight, salmon sperm) was purchased from Fluka 
(St. Louis, MO, USA). All other reagents were purchased 
from Sigma-Aldrich.
Fluorescence spectroscopy was performed with a Perkin 
Elmer LS55 spectrometer Perkin Elmer, Wellesley, MA, 
USA). To prepare fluorescence samples, the only opera-
tion was the mixing of two solutions before fluorescence 
measurements. X-ray photoelectron spectroscopy (XPS) 
measurements were carried out using a Leybold LHS 
10 spectrometer (Leybold, Cologne, Germany).
To the best of our knowledge, most of these fullerenols 
are not pure C60(OH)n, but a complex mixture of products. 
For instance, those synthesized through sulfuric/nitric acid,56 
hydroboration,57 or nitronium chemistry58 afforded products 
with average composition of C60Ox(OH)y. The so-called 
fullerenols prepared by alkaline polyhydroxylation of C60 
under phase transfer conditions59 are not simply C60(OH)x, 
but stable radical anions with the molecular formula, 
Na+
n[C60Ox(OH)y]n-,60 and the fullerenol obtained by 
alkaline hydrolysis of C60Br24 is not C60(OH)24 as claimed by 
Bogdanovi and Dvordjevic,37,61 but C60(ONa)8(OH)16.62 In the 
light of this, many biomedical studies involving fullerenols 
species in the literature may need to be reconsidered. The 
pure fullerenol C60(OH)24 used in this study was prepared 
by a modified method of alkaline hydrolysis of C60Br24,62 
followed by demetallation of the obtained C60(OK)8(OH)16 
with a cation exchange resin and exhaustive purification by 
dialysis.
Representative procedure for synthesis 
of c60(Oh)24
All experiments were performed with Schlenk techniques 
under argon and protected from light. According to the 
literature, before the synthesis of the polyhydroxylated 
fullerene, bromofullerene C60Br24 was synthesized first.62 
In the synthesis of the C60(OH)24, to a sonicated (40 W, 
15 min) suspension of C60Br24 (200 mg, 0.075 mmol) in 
de-aerated water (100 mL), fresh KOH (200 mg, 3.57 mmol) 
was added under argon protection and stirred for 10 days at 
room temperature. After the reaction was completed, the 
resulting dark-brown solution was passed to a centrifuge 
at 4000 rpm for 30 min and the supernatant was brought to 
dryness in a rotavapor apparatus at 40 °C. The dark-brown 
residue was dissolved in 50 mL of deionized water, stirred 
with ion exchange resin AMBERJET™ 1200[H] (Rohm and 
Haas Company, Philadelphia, PA, USA) (20 mL) for 8 h 
and subjected to dialysis (Spectra/Por® 1000 D; Spectrum 
Laboratories, Rancho Dominguez, CA, USA) for four 
days. Finally, the dialyzed solution was brought to dryness 
in a rotavapor apparatus at 60 °C and dried at 80 °C and 
10-4 Torr for 24 h. The fullerenol thus obtained contained 
24 hydroxyl groups as characterized by elemental analysis, 
Fourier transform infrared (FT-IR) spectroscopy, and XPS 
spectroscopic measurements.
elemental analysis
Calculated for C60H24O24: C, 63.82; H, 2.12. Found: C, 63.66; 
H, 1.98. FTIR (KBr): ν max, 3436 (-OH), 1605 (C = C), 
1430 (δ –OH), 1095, 1046 (ν C-OH), 1018, 994, 825, 877, 
570, 530 cm-1.
XPs analysis
C1s components: % C = C (284.6 eV) 59.77 (clcd. 60); 
% C-OH: (285.8 eV) 39,76 (clcd. 40); O/C = 0.42 (clcd. 0.40).
Results and discussion
The fullerenol water solution, exhibited different maxima 
depending on the concentration (Figure 1a). In the range of 
1.6 × 10-5 to 4.4 × 10-5 molL-1 one fluorescent maximum 
was observed at 469 nm, while two fluorescence maxima 
where found for lower concentrations located at 469 nm and 
492 nm at λex = 420 nm.
These emission profiles of fullerenol at different concen-
trations provided the baseline for understanding perturbation 
upon interaction with dsDNA. As shown in Figure 1a, the 
most appropriate concentrations of fullerenol in water for 
fluorescence measurements at λex = 420 nm are within the 
range of 1.6 × 10-5 to 4.4 × 10-5 molL-1 (λem = 469 nm).
As can be seen from Figure 1b, the fluorescence intensity 
of fullerenol alone is dependent on its concentration in the 
range of 4.4 × 10-5 to 1.6 × 10-5 molL-1 according to a very 
significant linear relationship.
Figure 2 shows the fullerenol and DNA emission spectra 
recorded at different excitation wavelengths. Inspection of 
how fluorescence emission spectra of fullerenol and DNA 
change as a function of excitation wavelength yield additional 
supporting information on the appropriate fullerenol excitation 
wavelength suitable for the fluorescence investigation of 
C60(OH)24 – DNA complex in aqueous media. One can observe 
that for a concentration higher than 1.6 × 10-5 molL-1, the 
emission spectra of fullerenol do not overlap with emission 
spectra of DNA when excited at 340, 360, 380, and International Journal of Nanomedicine 2009:4 195
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420 nm, respectively. Apparently, all these fluorescence 
excitations should be suitable for a fluorescence study of 
DNA-fullerenol interaction. However, the emission maxima 
of fullerenol at concentrations 1.6 × 10-5 molL-1 (Figure 1a) 
and DNA (Figure 2a) overlap at 492 nm when recorded at 
λex = 420 nm. This is the reason why, to cover a large concen-
tration range (1-9-4.5-5 molL-1) of fullerenol, the fluorescence 
excitation at 420 nm and emission at 469 nm were used for 
fluorescence intensity measurements in this work.
In Figure 3a, the emission spectra of DNA-fullerenol 
complexes, with constant DNA concentration and increasing 
fullerenol content are shown. It can been seen that increasing 
the concentration of the fullerenol results in a strong increase 
in fluorescence intensity of fullerenol from 50 to 500 nm, 
without causing any perceptible shifts of the fluorescence 
maximum at λ = 469 nm. In order to establish the DNA 
binding affinity of fullerenol, these fluorescent-enhancing 
data were plotted (Figure 3b) according to the equation (6) 
derived from the equilibrium equation (1):
n[C (OH) ] + [DNA]   [C (OH) DNA]
 
60 24 60 24
K       -   (1)
  K = [C60(OH)24 - DNA]/[C60(OH)24]n [DNA]  (2)
  [C60(OH)24 - DNA] = K[C60(OH)24]n [DNA]  (3)
log [C60(OH)24 - DNA] = log K + nlog [C60(OH)24] + log [DNA]
  (4)
log [C60(OH)24 - DNA]/[DNA] = log K + nlog [C60(OH)24]
  (5)
  log F-F1/F0 = log K + nlog [C60(OH)24]  (6)
where F1 is the fluorescence intensity from the fullerenol 
in the absence of DNA (Figure 1b), F0 is the fluorescence 
intensity from the DNA in the absence of fullerenol at 
467 nm for λex = 420 ( Figure 2a), F is the fluorescence 
intensity from the DNA-fullerenol complex in the presence 
of different concentrations of the fullerenol (Figure 3b) and 
n is the number of associated molecules of fullerenol with 
one base pair of DNA. From the linear plot for (log(F-F1)/F0) 
vs (log[C60(OH)24]) (Figure 5), according to equation (1), 
the values of K and n were estimated to be 6 × 105 M-1 and 
0.8 ± 0.2, respectively.
In order to evaluate the range of [DNA] determina-
tion, the binding of fullerenol to DNA was characterized 
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Figure 1 Fluorescence data of c60(Oh)24 in aqueous media.  A) Fluorescence emission 
spectra of c60(Oh)24 after 5 min incubation in water, with excitation at 420 nm. 
B) Plot of fluorescence intensity versus [C60(Oh)24], with excitation at 420 nm; 
average standard error, 3.76%.
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Figure 2 Fluorescence emission spectra of fullerenol ( - - - ) and dsDNA (_____) 
for different excitation wavelength.  A) λ = 420 nm. B) λ = 380 nm. C) λ = 360 nm. 
D) λ = 340 nm. [C60(Oh)24] = 1 × 10-4 molL-1; [DNA] = 1 × 10-4 molL-1.International Journal of Nanomedicine 2009:4 196
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through fluorescence emission titration of fullerenol. The 
enhancement of the fluorescence intensity of fullerenol with 
DNA at increasing concentrations is shown in Figure 4. 
One can observe that even for nanoscale concentration 
of DNA the fluorescence intensity of fullerenol increases 
from 25 to 100 (Figure 4a). The plot in Figure 4b is bro-
ken down into two regimes corresponding to ranges from 
1.3 × 10-9 to 3.1 × 10-6 gL-1 and 2.5 × 10-5 to 5 × 10-5 gL-1. 
The low [DNA] range in the plots of Figure 4b (detec-
tion limit = 1.3 ng/mL) are close to what can be accom-
plished with current available fluorescence probes, ie, 
Hoechst 33258 (20 ng/mL) and YO-PRO-1/YOYO-1 
(0.5–2.5 ng/mL). In addition, from the shape and intensity of 
emission spectrum recorded for [DNA] = 2.1 × 10-9 molL-1 
(Figure 4a), it is useful to point out that the sensitivity can 
be extended into lower regions.
As regards the chemical interactions between fullerenol and 
the DNA target, the electrostatic and intercalative binding are 
ruled out and hydrogen-bonding interaction can only be taken 
under consideration. Earlier studies38,39 have pointed out that 
hydrogen-bonding plays the main role in the interaction between 
fullerenols and proteins. Thus, the major groove binding of fullere-
nol through the hydrogen-bonding between its hydroxyl groups 
and free or bridged –NH2 in base-pairs of DNA is predictable.
Taking into account that phenols can interact with 
phosphates,63 the hydrogen bonding between fullerenol and 
phosphate backbone of DNA can be also suggested as a 
possibility for the binding of fullerenols with DNA.
From the linear plot in Figure 3b according to equation (1) 
the value of n was estimated to be 0.8 ± 0.2. This value 
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Figure 3 Fluorescence data of c60(Oh)14 in the presence od dsDNA. A) Fluorescence 
emission spectra of fullerenol (_____) in the presence of dsDNA ( - - -) with excitation at 
420 nm, as a function of fullerenol concentration; [dsDNA] = 6.31 × 10-5 molL-1. B) Plot 
for DNA-c60(Oh)24 system as a function of fullerenol concentration in the range of 0.94 × 
10-7 to 4.5 × 10-5 molL-1; [dsDNA] = 6.31 × 10-5 molL-1; average standard error, 0.17%.
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Figure 4 Dependence of fluorescence intensity of C60(Oh)24 on dsDNA concentration. 
A) Fluorescence spectra of fullerenol (- ⋅ -  ) with increasing concentration of DNA 
(_____) with excitation at 420 nm ; B) Plot of fluorescence intensity of fullerenol as a 
function of [dsDNA] in the concentration range of 1.3 × 10-9 to 4.4 × 10-6 molL-1; 
[C60(Oh)24] = 4.5 × 10-5 molL-1; average standard errors: 2.69% for 2.5e-5-5e-5 region 
and 10.80% for 1.3e-9-3.1e-6 region.International Journal of Nanomedicine 2009:4 197
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groove of DNA (6 Å). The width of the major groove (12 Å) 
is larger than 9.8 Å and thus the fullerenol molecule can fit 
snugly according to a nonintercalation model as shown in 
Scheme 1a.
Indeed, upon binding to sodium salt of DNA (Figure 5), 
the fluorescence intensity of fullerenol does not increase, 
but decreases, which suggests that only in the absence of 
hydrogen bond-forming P-OH moieties of DNA, fullerenol 
binds to base-pairs into the major groove of DNA, according 
to a nonintercalative model, which strongly change its 
average local environment. The perceptible shift of the 
emission maximum of fullerenol also support a strong 
change of its average local environment. We can thus 
conjecture that, under the present experimental condi-
tions with native dsDNA, hydrogen binding to phosphate 
backbone to the outside of dsDNA helix is the main bind-
ing mode of fullerenol C60(OH)24 to DNA, as shown in 
Scheme 1b.
Conclusions
Fullerenol C60(OH)24 binds to phosphate backbone to the 
outside of native dsNNA and to base-pairs within major 
groove of sodium salt of dsDNA. The fluorescence of 
fullerenol C60(OH)24 is highly enhanced by dsDNA due 
to the binding of the probe to DNA in a nonintercalative 
way. Because of its high binding affinity (K = 105 M-1) and 
sensitivity (1.2 × 10-9 g/mL) towards DNA, there are good 
prospects that C60(OH)24 will be used as versatile fluorescent 
probe for DNA quantification. In addition to its high 
sensitivity, other advantages of this fullerenol-based method 
include its simplicity, nontoxicity, and rapidity.
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